.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Queensland Health
Julphar
Cerilliant
Citi
Covington
McKesson
Medtronic
Harvard Business School
Daiichi Sankyo

Generated: February 21, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0019172.6

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes➤ Sign Up➤ Sign UpYOTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes➤ Sign Up➤ Sign UpY
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes➤ Sign Up➤ Sign UpY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes➤ Sign Up➤ Sign UpY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes➤ Sign Up➤ Sign UpY
GlaxosmithklineTRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION209482-001Sep 18, 2017RXYesYes➤ Sign Up➤ Sign UpY
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist